| abstract |
The present invention relates to c-Met antibody and c-Met antibody-cytotoxic drug conjugates and pharmaceutical use thereof. In particular, the present invention relates to a c-Met antibody, antigen binding fragment thereof, chimeric or humanized antibodies comprising the c-Met antibody CDR regions, and ADC thereof, a pharmaceutically acceptable salt or solvate thereof. And pharmaceutical composition comprising the humanized c-Met antibodies, antigen-binding fragments, ADC, or a pharmaceutically acceptable salt or solvate thereof, and their use as anti-cancer agents, especially their use in the preparation of a medicament for the treatment of c-Met-mediated disease or symptom. |